Breast cancers with HER2 gene amplification and/or protein overexpression have been shown to be responsive to trastuzumab (Herceptin), a humanised monoclonal antibody directed against the extracellular domain of HER2 (Baselga, 2001; Arteaga and Baselga, 2004). This evidence concerns the gene ERBB2 and breast carcinoma.